Navigation Links
For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
Date:4/23/2013

BURLINGTON, Mass., April 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the numerous therapies in clinical development for extensive-disease small-cell lung cancer (ED-SCLC), no emerging therapy is likely to replace etoposide (Bristol-Myers Squibb's Etopophos/VePesid, generics)/carboplatin (generics) as the standard of care before 2022. Interviewed experts complain that treatment for SCLC has changed very little in decades, and—given the challenges of treating this aggressive disease and the current clinical pipeline—experts are pessimistic that the treatment landscape will improve in the near future.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled How Receptive Would Oncologists and Payers Be to Therapies That Partially Address the Unmet Needs of Patients with Advanced Disease? finds that surveyed U.S. and European oncologists agree that increasing overall survival (OS) is one of the greatest unmet needs in ED-SCLC. Despite high response rates with first-line therapy, most patients relapse within a year after treatment and survival rates remain dismal. Experts admit that, should efficacy benefits be seen with therapies in development—such as Ziopharm Oncology's Zymafos, Bristol-Myers Squibb's Yervoy, Genentech/Roche/Chugai's Avastin or Immunogen's lorvotuzumab mertansine—these benefits will likely be only incremental improvements that will not transform current treatment practice. According to the findings, a drug that offers marked improvement in survival presents a strong commercial opportunity to developers, although no drug in clinical development is expected to imp
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... of "Quality Affordable Healthcare Products®," today announced the closing ... the sale of 6,809,210 ordinary shares at a public ... exercise of the option to purchase up to an ... and Barclays Capital Inc., as representatives of the several ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
(Date:11/26/2014)... Nov. 26, 2014  Over 100 million adults suffer ... from this pain daily. Chronic and acute pain dramatically ... is born to fulfill the need for non-surgical, interventional ... pain. On October 28th, a new pain ... Cumberland, Maryland community.  This new facility boasts ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... 9, 2010 PAREXEL International Corporation (Nasdaq: PRXL ... Capital Markets Healthcare Conference in New York.  Josef von Rickenbach, ... on PAREXEL at 1:10 p.m. ET on Tuesday, November 16, ... be available through the "Investors" section of PAREXEL,s website at ...
... Incorporated (Nasdaq: ARAY ), a global leader in the ... of fiscal year 2011, ended September 30, 2010. ... of $38.1 million, a decrease over the first quarter of fiscal ... for the first quarter of fiscal 2011 was $4.6 million, or ...
Cached Medicine Technology:PAREXEL International to Participate in the Lazard Capital Markets Healthcare Conference in New York and the Jefferies Healthcare Summit in Boston 2Accuray Announces Results for First Quarter of Fiscal 2011 2Accuray Announces Results for First Quarter of Fiscal 2011 3Accuray Announces Results for First Quarter of Fiscal 2011 4Accuray Announces Results for First Quarter of Fiscal 2011 5Accuray Announces Results for First Quarter of Fiscal 2011 6
(Date:11/27/2014)... According to a recent report by iData Research ... the surgical robotics market may find significant ... field dominated by Intuitive. These companies are expected to ... by 2020. , “The MIS robotic device market ... President of iData. “System sales for the da Vinci ...
(Date:11/27/2014)... Luciana Lagana and her husband ... Omadox, a feature film that received 9 awards at the ... ensemble cast. It is also an official selection of the ... a successful cinematic career for James Noel, a young filmmaker ... enjoy experimental mystery, filmed in glorious black and white, watching ...
(Date:11/27/2014)... 27, 2014 Cambrionix Ltd today announced that ... 50, a ranking of the 50 fastest-growing technology companies in ... over the last five years. Cambrionix Ltd grew 2989 ... first in the region of Cambridgeshire and East and first ... Says:, “This award is recognition of the hard work put ...
(Date:11/27/2014)... Acapulco, Guerrero (PRWEB) November 27, 2014 ... the time individuals allot to sleep has lessened, ... televisions and laptops, the quality of sleep has ... workers falls asleep on the job (Reference: ... American worker’s productivity index by an incalculable amount, ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of ... procedures in place to counter this. However, it doesn’t ... tainted with menstrual blood are taken as seriously. ... sanitary way to handle tampons and menstrual pads while ... Calif. , He then created a prototype of the ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... Rheumatism (EULAR) welcomes the outcomes of yesterday,s Council of ... 7 December, ministers for health adopted Council Conclusions on ... States and the European Commission to adopt concrete, coordinated ... pleased to note that the Council Conclusions reflect many ...
... (HealthDay News) -- ,Women with localized breast cancer are less ... surgery, a new study finds. The researchers also found ... of the recurrence of localized cancer. The three-nation study ... common type of noninvasive breast cancer, who were followed for ...
... MDA recent study accepted for publication in The Endocrine ... (JCEM) has demonstrated a novel and accurate test for ... in 1,500 to 2,000 female live births and early ... and co-morbid conditions including cardiac and renal problems. ...
... CA (December 8, 2010) People who are neurotic often ... neurotic newlyweds have frequent sexual relations, their marital satisfaction ... counterparts, according to a study in the current ... Neuroticism is the tendency to experience negative ...
... HealthDay Reporter , TUESDAY, Dec. 7 (HealthDay News) -- Stool ... accurate for patients on a low-dose aspirin regimen, which is ... While therapeutic aspirin use was once feared to skew ... researchers found the test was significantly more sensitive for low-dose ...
... can be a life saver for patients needing immediate ... the process of activating them often delays treatment beyond ... print in Annals of Emergency Medicine, was ... multicenter, retrospective chart review, McMullan found that a majority ...
Cached Medicine News:Health News:EULAR welcomes Council action to tackle chronic diseases 2Health News:Radiation After Surgery Lowers Chances of Breast Cancer's Return 2Health News:Frequent sex protects marital happiness for neurotic newlyweds 2Health News:Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test 2Health News:Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test 3Health News:Even with helicopter EMS, hospital transfer can delay treatment for heart attacks 2Health News:Even with helicopter EMS, hospital transfer can delay treatment for heart attacks 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: